OBJECTIVETo update the current status of bioresorbable scaffold, highlights the potential future prospective of innovative bioresorbable scaffold technology.

DATA SOURCESData were obtained from papers published in PubMed, presentations from the following conferences: EuroPCR, Transcatheter Cardiovascular Therapeutics, and Chinese Interventional Therapeutics.

RESULTSBioresorbable scaffold has been introduced as a potential workhorse device for the treatment of coronary artery disease, with providing temporary vessel scaffold, then gradually being resorbed free of any caging, eventually restoring the vessel wall physiology and vasomotion. The clinical outcomes regarding the safety and efficacy following bioresorbable scaffolds implantation appear promising in the treatment of patients with either de novo lesions or acute myocardial infarction (AMI). In addition, two bioresorbable scaffolds currently investigated in Chinese population as well as several other bioresorbable scaffolds from Chinese manufactories are under development and preclinical evaluations.

CONCLUSIONSBioresorbable scaffolds with potential unique advantages have been rapidly developed and the initial clinical results are promising. Further preclinical and clinical evaluations are necessary to investigate their safety and efficacy in the treatment of Chinese patients with coronary artery disease.